- Home
- CIM vs PHAR Comparison
CIM vs PHAR Comparison
Compare CIM & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIM
- PHAR
- Stock Information
- Founded
- CIM 2007
- PHAR 1988
- Country
- CIM United States
- PHAR Netherlands
- Employees
- CIM N/A
- PHAR N/A
- Industry
- CIM Real Estate Investment Trusts
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- CIM Real Estate
- PHAR Health Care
- Exchange
- CIM Nasdaq
- PHAR Nasdaq
- Market Cap
- CIM 1.1B
- PHAR 951.7M
- IPO Year
- CIM 2007
- PHAR N/A
- Fundamental
- Price
- CIM $13.06
- PHAR N/A
- Analyst Decision
- CIM Buy
- PHAR Strong Buy
- Analyst Count
- CIM 3
- PHAR 3
- Target Price
- CIM $15.50
- PHAR $30.00
- AVG Volume (30 Days)
- CIM 683.7K
- PHAR 14.9K
- Earning Date
- CIM 11-05-2025
- PHAR 10-23-2025
- Dividend Yield
- CIM 11.36%
- PHAR N/A
- EPS Growth
- CIM N/A
- PHAR N/A
- EPS
- CIM 1.28
- PHAR N/A
- Revenue
- CIM $312,281,000.00
- PHAR $339,836,000.00
- Revenue This Year
- CIM $15.99
- PHAR $17.44
- Revenue Next Year
- CIM $9.70
- PHAR $8.46
- P/E Ratio
- CIM $10.14
- PHAR N/A
- Revenue Growth
- CIM 1.91
- PHAR 22.44
- 52 Week Low
- CIM $9.85
- PHAR $7.31
- 52 Week High
- CIM $16.27
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- CIM 32.06
- PHAR 50.22
- Support Level
- CIM $12.95
- PHAR $13.18
- Resistance Level
- CIM $13.57
- PHAR $16.29
- Average True Range (ATR)
- CIM 0.22
- PHAR 0.51
- MACD
- CIM -0.08
- PHAR -0.10
- Stochastic Oscillator
- CIM 8.63
- PHAR 36.21
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.